Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 1 of 39 
  
CLotTriever OUT comes (CLOUT)  
 Registry  
 
  
 
Device: ClotTriever® Thrombectomy System  
Protocol Number : 18-001 
Version: 9.0 
August 12, 2020  
  
Sponsor  
Inari Medical  
9 Parker, Suite 100  
Irvine, CA 92618  
USA 
 
   CONFIDENTIALITY STATEMENT  
This Clinical Investigation Plan  and all attachments are considered confidential information. The contents must  not 
be disclosed , unless authorized in writing by Inari Medical , except that this document may be disclosed  to the 
appropriate Institutional Review Board (IRB) or duly authorized representative of the U .S. Food and Drug 
Administration with similar requests for maintenance of confidentiality. All data and study results are similarly 
subjected to the same  disclos ure restrictions as the investigational plan, as s tated above. All copies of this 
investigational plan  remain the property of Inari Medical . 
 
 

Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 2 of 39 
 TABLE OF CONTENTS  
Table of Contents ................................................................................................................................................... 2 
Protocol Signature Page  ......................................................................................................................................... 5 
Synopsis  ............................................................................................................................................................ 6 
Abbreviations  ........................................................................................................................................................ 9 
1 INTRODUCTION AND BACKGROUND  ............................................................................................................. 10 
1.1 Deep Vein Thrombosis: Definition, Anatomy, and Pathophysiology  .................................................... 10 
1.2 Complications of DVT ......................................................................................................................... 10 
1.3 Medical and Economic Impact of DVT  ................................................................................................ 11 
1.4 DVT Treatment and Current Shortcomings  ......................................................................................... 11 
1.5 Rationale for the ClotTriever Thrombectomy System  ......................................................................... 12 
2 STUDY DEVICE  ............................................................................................................................................... 12 
2.1 Overview  ........................................................................................................................................... 12 
2.2 Manufacturer  .................................................................................................................................... 12 
2.3 Indications for Use  ............................................................................................................................. 13 
2.4 Device Description  ............................................................................................................................. 13 
3 PRIOR INVESTIGATIONS  ................................................................................................................................ 13 
4 STUDY OBJECTIVES ........................................................................................................................................ 13 
5 OUTCOME VARIABLES  ................................................................................................................................... 14 
5.1 Primary Safety Endpoint Definition  .................................................................................................... 14 
5.2 Primary Effectiveness Endpoint Definition .......................................................................................... 14 
5.3 Secondary Endpoints  ......................................................................................................................... 14 
6 STUDY DESIGN  .............................................................................................................................................. 15 
6.1 Study Populations  .............................................................................................................................. 15 
6.2 Informed Consent  .............................................................................................................................. 15 
6.3 Point of Enrollment ............................................................................................................................ 16 
6.4 Inclusion Criteria ................................................................................................................................ 16 
6.5 Exclusion Criteria  ............................................................................................................................... 16 
7 ASSESSMENTS AND FOLLOW -UP SCHEDULE .................................................................................................. 17 
7.1 Schedule of Assessments  ................................................................................................................... 17 
7.2 Baseline Assessment  .......................................................................................................................... 18 
7.3 Index Procedure  ................................................................................................................................ 19 
7.4 Target Vessel Segment (TVS) Assignment  ........................................................................................... 19 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 3 of 39 
 7.5 Clinic/Hospital Discharge  Assessment .................................................................................................  20 
7.6 Follow -Up Assessments and Windows ................................................................................................ 20 
7.7 Procedures, Reinterventions, and Rethrombosis  ................................................................................ 20 
7.8 Unscheduled Follow -up Visits  ............................................................................................................ 21 
7.9 Withdrawals and Lost to Follow -up .................................................................................................... 21 
7.10 COVID -19 Effect on Research  ............................................................................................................. 21 
8 RISK ANALYSIS  .............................................................................................................................................. 22 
8.1 Risks to the Subjects  .......................................................................................................................... 22 
8.2 Risk Mitigation  ................................................................................................................................... 22 
9 Safety Assessments  ....................................................................................................................................... 22 
9.1 Defining Adverse Events  .................................................................................................................... 22 
9.2 Reporting Adverse Events  .................................................................................................................. 23 
10 STATISTICS AND DATA ANALYSIS  .................................................................................................................. 24 
10.1 Statistical Methodology  ..................................................................................................................... 24 
10.2 Primary Safety Endpoint Analysis  ....................................................................................................... 24 
10.3 Primary Effectiveness Endpoint Analysis  ............................................................................................ 24 
10.4 Study Success Criteria  ........................................................................................................................ 25 
10.5 Missing Data  ...................................................................................................................................... 25 
10.6 Safety Performance Goal Derivation  .................................................................................................. 25 
10.7 Effectiveness Performance Goal Derivation  ........................................................................................ 25 
10.8 Sample Size  ....................................................................................................................................... 25 
10.9 Continued Enrollment Beyond the Primary Analysis Dataset  .............................................................. 26 
10.10  Demographics and Baseline Characteristics  ........................................................................................ 26 
10.11  Subgroup and Other Analyses  ............................................................................................................ 27 
10.12  Data Poolabi lity Assessment  .............................................................................................................. 27 
11 STUDY MANAGEMENT CONSIDERATIONS  ..................................................................................................... 28 
11.1 Data Manage ment: Clinical Data  ........................................................................................................ 28 
11.2 Protocol Modifications ....................................................................................................................... 28 
11.3 Protocol Deviat ions ........................................................................................................................... 28 
11.4 Information to Study Personnel  ......................................................................................................... 29 
12 STUDY ADMINISTRATION .............................................................................................................................. 29 
12.1 Site Initiation  ..................................................................................................................................... 29 
12.2 Study Monitoring  ............................................................................................................................... 29 
12.3 Study Termination  ............................................................................................................................. 29 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 4 of 39 
 12.4 Data Handling and Recordkeeping  ..................................................................................................... 30 
13 ETHICS  .......................................................................................................................................................... 31 
13.1 Informed Consent  .............................................................................................................................. 31 
13.2 Institutional Review Board (IRB)  ......................................................................................................... 31 
13.3 Confidentiality Regarding Study Subjects  ........................................................................................... 31 
13.4 Independent Medical Monitor  ........................................................................................................... 32 
13.5 Core Laboratory and Image Transfer  .................................................................................................. 32 
13.6 Participating Institutions and Investigators ......................................................................................... 32 
13.7 Investigator Responsibilities  .............................................................................................................. 32 
14 ELECTRONIC DATA  ........................................................................................................................................ 32 
15 DEFINITIONS  ................................................................................................................................................. 33 
16 REFERENCES  .................................................................................................................................................. 36 
APPENDIX 1  KNOWN RISKS OF THROMBECTOMY  ........................................................................................... 38 
SIGNATURE APPROVAL PAGE ............................................................................................................................... 39 
 
LISTING OF TABLES  
 
Table 1. Schedule of Assessments  ........................................................................................................................ 17 
Table 2. Sample Size -  Primary Safety Endpoint  ................................................................................................... 25 
Table 3. Sample Size -  Primary Effectiveness Endpoint ......................................................................................... 26 
 
  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 5 of 39 
 PROTOCOL SIGNATURE PAGE 
 
   
Investigator Name   Title  
   
Site Name   Site Number  
 
 I have read the protocol and agree that it contains all necessary  details for carrying out this study. I will conduct 
the study as outlined therein.  
I will provide copies of the protocol and all information on the device relating to past non -clinical and clinical 
experience, which were furnished to me by the S ponsor, to all physicians and other study person nel responsible to 
me who participate in this study and  will discuss this material with them to ensure that they are fully informed 
regarding the device and the conduct of the study.  
I agree to keep records on all subject information (e. g., source documents  and informed consent forms ) and all 
other information collected during the study, in accordance with local and national regulations.  
 
   
Investigator’s Signature    Date  
   
  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 6 of 39 
 SYNOPSIS   
Protocol Number  18-001 
Study Title  ClotTriever Outcomes (CLOUT) Registry  
Study Device  ClotTriever® Thrombectomy System  
Regulatory Status  The ClotTriever Thrombectomy System was cleared  in the US  under 510(k) number 
K163549, February 16, 2017. The device is indicated  for the non -surgical removal of soft 
thromb i and emboli from peripheral blood vessels.  
Sponsor  Inari Medical 
9 Parker, Suite 100 
Irvine, CA 92618 (USA) 
Primary Study  
Objective  The primary objective of this study is to evaluate real world patient outcomes after  
treatment of acute , subacute , and chronic  proximal lower extremity deep venous 
thrombosis  (DVT)  with the ClotTriever Thrombectomy System . 
Study Population  The Full Analysis dataset comprises up to 500 subjects with proximal lower extremity  
DVT.  
The Prima ry Analy sis dataset s are subset s of the Full Analy sis dataset, comprising 91 
subjects with unilateral acute or  subacute  DVT of less than  or equal to  6 weeks’ 
duration.  
• Primary Safety Cohort  are subjects in the Primary Analy sis dataset who were not  
treated with thrombolytic or percutaneous mechanical thrombectomy within the 
prior 3 months.  
• Primary Effectiveness  Cohort  are subjects in the Primary Analy sis dataset with 
core laboratory -documented intraluminal thrombus at baseline who have at least 
one target venous segment (TVS) treated with the study device.  
Number of Sites  The study will be conducted at up to 50 sites.  
Study Design  The CLOUT Registry is a prospective, multi- center, observational study of subjects with 
proximal lower extremity DVT treated with the ClotTriever T hrombectomy System. The 
Registry will collect data on demographics , comorbidities , details from  the DVT 
diagnosis and treatment, and clinical outcomes through 2 -year follow -up.  
Primary Endpoints  
(Primary Analysis 
Cohort s) Primary Safety Endpoint:  
Composite of Major Adverse Events  (MAEs)  through 30 days  defined as one or more of 
the following : 
• All-cause mortality  
• Major bleeding  
• New symptomatic PE documented by  CTPA   
• Rethrombosis of a  TVS 
 
Primary Effectiveness Endpoint : 
Technical Success defined as complete or near complete (≥75%) removal of venous thrombus from the TVS. 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 7 of 39 
 Secondary Endpoints  
(Primary Analysis 
Cohort s) The following will be assessed as secondary endpoints of the study:  
• Individual co mponents of the MAE composite endpoint  through 30 days  
• Minor bleeding  through 30 days  
• Access site complications from the index procedure (hematoma, false aneurysm, 
perforation)  through 30 days  
• Device -related death  
• Procedure -related death  
• At any point during follow -up: 
o TVS patency by duplex ultrasound  
o Rethrombosis of the TVS   
o Device -related  rethrombosis of the TVS  
o DVT outside of the TVS 
o Target limb edema (edema scale of the rVCSS)  compared to baseline  
o Pain (NPRS) compar ed to baseline  
o EQ-5D, rVCSS, Villalta scores compar ed to baseline  (except discharge)  
Inclusion Criteria  Subjects must meet the following criteria to be included in the study:  
1. Age ≥ 18 year s 
2. Proximal lower extremity DVT involving the femoral, common femoral, iliac veins 
or inferior vena cava (IVC), alone or in combination  
3. Willing and able to provide informed consent  
Exclusion Criteria:  Subjects will be excluded from the study f or:  
1. Prior venous stent i n a TVS 
2. IVC aplasia/hypoplasia or other congenital anatomic anomalies of the IVC or iliac veins  
3. IVC filter in place at the time of the index procedure  
4. Allergy, hypersensitivity, or thrombocytopenia from heparin or iodinated 
contrast agents, except for mild to moderate contrast allergies for which 
pretreatment can be used  
5. Life expectancy less than 1 year  
6. Chronic non -ambulatory status  
7. Known hypercoagulable  states that, in the opinion of the Investigator, cannot be 
medically managed  throughout the study period  
8. Unavailability of a proximal lower extremity venous access site  
Follow -Up Schedule  Subjects will have required follow -up evaluations afte r the index p rocedur e at: 
discharge , 30 days , 6 months, 1 year, and  2 years . 
Primary Analysis Sample Size  
Calculation   The sample size is driven by the primary safety endpoint. A performance goal of 3 4% 
has been established, based on a one -sided 97.5% exact binomial test. The 30 -day MAE 
rate is anticipated to be approximately 20%. Under these assumption s, the required 
sample size to achieve a level of 82% power is 86 subjects. Assuming 5% attrition over 
30 days, a sample size of 91 subjects is necessary.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 8 of 39 
 Analytic Datasets  In total, up to 500 subjects may be enrolled in the Full Analysis  dataset.  The Primary 
Analy sis dataset will comprise subjects with unilateral acute or subacute DVT of less 
than or equal to 6 weeks’ duration, without recent ( ≤3 month) venous interventions.  
 
The first 91 subjects enrolled in the Primary Analy sis dataset will comprise the Primary 
Anal ysis Safety cohort  for safety  assessment . Effectiveness  will be  evaluated in the 
primary analysis cohort with core lab adjudication of intraluminal thrombus.  
Medical Monitor  An independent Medical Monitor will review adverse events  and other important safety 
occurrences as specified in the Safety Plan.  
National Principal 
Investigator s Robert Beasley, M.D.  
Mount Sinai Medical Center  
Miami Beach, FL  
 
David Dexter , M.D. 
Sentara Healthcare  
Norfolk, VA  
Schedule of Assessments  
Assessment  Baseline *      
(-7 to 0 days)  Index 
Procedure  
(day 0)  Discharge  30 Days  
(14 to 45 days)  6 Months  
(46 to 270 days)  1 Year  
(271  to 540 days)  2 Years  
(541  to 900 days)  Unscheduled 
Visits  
Medical  history  X        
Physical examination†  X  X X X X X X 
Inclusion/exclusion criteria  X        
Anticoagulation regimen  X X X X X X X X 
Duplex ultrasound§ X   X X X X X 
Venogram  (Required)   2x+       
IVUS  (Expected)   2x+       
Access site e xamination    X X     
Adverse event  assessment   X X X X X X X 
CEAP Score║ X        
EQ-5D, Villalta, rVCSS  Quality 
of Life Assessments  X   X X X X  
Edema  and Numeric Pain 
Rating Scale (NPRS)  
assessment  X  X X X X X  
*Baseline  assessments must be performed no more than 7 days prior to the index procedure or after the onset of symptoms in those subjects with 
less than 7 days’ symptom duration. 
†Physical examination is limited to the involved lower extremity(ies). Examination will include an assessme nt of leg edema, graded as per the rVCSS 
scale; mild (limited to foot and ankle), moderate (above ankle but below knee), or severe (knee and above), and recorded on t he right and left legs. 
§Duplex ultrasound will include patency assessments of all target lesions including flow (present , absent, or not evaluable ) and compressibility 
(normal, partial, incompressible, not evaluable ). 
+ Imaging will be captured before C lotTriever  treatment and after  ClotTriever  treatment but before adjunctive therapy (i f any). If adjunctive therapy is 
utilized , a third set of images will be obtained  afterwards . In addition, if a reintervention is performed, the same imaging timing and transfer are 
required.  Note that adjunctive therapy is defined as an additional thrombus removal strategy after ClotTriever thrombectomy has been completed 
(i.e. balloon, stenting , and placement of IVC filters during ClotTriever procedure session would NOT be considered adjunctive therapy).  
║CEAP (Clinical, Etiologic , Anatomic , and Pathophysiologic ) score is a clinical classification score developed to allow uniform diagnosis and 
stratification of patient populations according to the severity of their presentatio n 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 9 of 39 
 ABBREVIATIONS  
Abbreviation  Term  
AE Adverse Event  
ATTRACT  Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter -Directed Thrombolysis  
BMI Body Mass Index, calculated as weight in k g divided by height in m squared  
CDT Catheter Directed Thrombolysis  
CEAP  Clinical, Etiologic, Anatomic, Pathophysiologic  
CFR Code of Federal Regulations  
CRF Case Report Form  
CRO  Contract Research Organization  
CT ClotTriever  
CTPA  Computed Tomography Pulmonary Angiogram  
DOAC  Direct Oral Anticoagulant  
DVT Deep Vein Thrombosis  
FDA US Food and Drug Administration  
HIPAA  Health Insurance Portability and Accountability Act  
ICU Intensive Care Unit  
IFU Instructions for Use  
IRB Institutional Review Board  
ISO International Organization for Standardization  
ITT Intent -to-Treat  
IVC Inferior Vena Cava  
IVUS  Intravascular Ultrasound  
LOS Length of Stay  
MAE  Major Adverse Event  in the ITT population  
MLA  Minimum Lumen Area  
MLD  Minimum Lumen Diameter  
NPRS Numerical  Pain  Rating Scale  
PE Pulmonary Embolism  
PHI Personal Health Information  
PMT  Percutaneous Mechanical Thrombectomy  
PP Per Protocol  
PTS Post -Thrombotic Syndrome  
RVA Reference Vessel Area  
RVD Reference Vessel Diameter  
rVCSS Revised Venous Clinical Severity Score  
TVS Target Venous Segment (s) 
VKA Vitamin K Antagonist  
VTE Venous Thromboembolism  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 10 of 39 
 1 INTRODUCTION  AND  BACKGROUND  
1.1 DEEP VEIN THROMBOSIS : DEFINITION , ANATOMY , AND PATHOPHYSIOLOGY  
Deep vein thrombosis (DVT) develops when a blood clot (thrombus) forms in a deep vein.1 Most DVT occur in the 
legs, but can also occur  in the arms, as well as the m esenteric and pelvic veins.2 Lower extremity DVT is classified 
as either proximal or distal.3 Proximal DVT is defined when the process involves  the iliac, deep femoral, or popliteal 
veins, whereas distal  DVT occur in the veins of the calf, most frequently in the posterior tibial and peroneal veins, 
and less frequently in the anterior tibial and soleal/gastrocnemius  veins.3,4 Notably, the risk of subsequent 
embolization in proximal DVT is double that of isolated distal DVT.3 Hence, proximal DVT ha ve a less favorable 
prognosis.5 Regardless of the vein in which it forms, DVT tend to originate on the v enous endothelium in regions of 
sluggish blood flow above and below venous valves.2,5  
The pathophysiology of DVT has been attributed to three principal  risk factors: a change in blood flow in the form 
of venous stasis, endothelial injury, and blood hypercoagulability –  known collectively as Virchow’s triad.6 Stasis 
sufficient to precipitate DVT can result from prolonged immobility, due to –  for example –  a long plane t rip or train 
ride, or secondary to a paralytic neurological injury.7 The significant role that venous stasis plays in the eti ology of 
DVT is most clearly demonstrated by the finding that stroke patients with hemiparesis have a sevenfold greater 
risk of developing DVT in their paralyzed leg relative to their non -paralyzed leg.6 Relevant causes of endothelial 
injury include trauma, recent surger y, and intravenous drug use.7 Hypercoagulability can stem from inflammatory 
conditions such as systemic lupus erythematosus o r inflammatory bowel disease, cancer, sepsis, previous 
thromboembolic disease, the nephrotic syndrome, or inherited or acquired thrombophilia.7-10 Additional risk 
factors that do not fit neatly into Virchow’s triad include pregnancy, oral contr aceptive use, cardiac disease, age 
greater than 60 years, cytotoxic chemotherapy, and obesity.7,9 Some risk factors are more consequential than 
others. For instance, paralytic neurological injury is significantly more dangerous than prolonged immobility.9 
Many DVT patients have multiple simultaneous risk factors. In one DVT patient cohort, 76 % of patients with DVT  
had two or more  risk factors, and 39 % had three or more.9 Moreover, these factors tend to be additive.7,9 Beyond 
those cases in which at least one risk factor is clearly present, some DVT are  idiopathic.5 
Venous thrombi  are made of a fibrin -bound aggregate of red blood cells, white blood cells, and platelets.2 They 
form when tissue factor is exposed, thrombin is created, and fibrinogen  is transformed into fibrin.8 Once the clots 
have formed, they often res olve – as least to some degree – on their own. Among one group of DVT patients, 86 % 
showed some degree of venous reopening (recanalization) within 3 months of the initial clotting event.5 The 
smaller the size of the thrombi, the more quickly and completely recanalization occurs.5 However, recanalization is 
not always the positive development one might suppose,  since it is when clots begin to migrate away from the 
veins and back toward the heart that some of the most significant DVT sequelae can arise. When they embolize, clots can find their way into the pulmonary circulation, where they can cause a pulmonary e mbolism (PE). They 
also have the potential to enter the arterial circulation by way of an atrial septal defect, or a patent foramen 
ovale.
8 
1.2 COMPLICATIONS OF DVT  
Some of the most important sequelae of DVT include PE, the post- thrombotic syndrome (PTS),  and the formation 
of recurrent  DVT. PE can lead to alveolar hyperventilation , diminished gas exchange, decreased pulmonary 
compliance, and increased airway resistance.2,8 This cascading chain of physiological derangements can eventually 
cause right heart failure, ultimately leading to death  in some cases.8 In PTS, incomplete recanalization after a DVT 
clot causes venous obstruc tion, which in turn results in venous hypertension. In response to this hypertension, 
capillaries dilate and become more permeable, which can cause localized edema, leg pain, eczema, and venous ulceration.
11 One additional complication of DVT is called phlegmasia cerulea dolens (blue, painful leg) in which a 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 11 of 39 
 large DVT totally blocks arterial flow , yielding limb discoloration and ischemia, venous gangrene, and systemic 
hypovolemic shock.  
DVT result in PE in 15 to 32 % of cases, and PTS in 56 % of cases.12 Because it is so comm on for DVT and PE to 
present concurrently , they are sometimes considered to be part of a single disease entity: venous 
thromboembolism  (VTE) .2 In addition, DVT has a recurrence rate – from time of initial diagnosis – of 10 % at 1 year, 
24%  at 5 years, and 30 % at 8 years.5,12 The case fatality rate among hospitalized patients with DVT is 5 %, and 5 -
year mortality can be as high as 39 %.5 Despite this, it is nonetheless important to bear in mind that in at least some 
cases, DVT does not result in any pathology whatsoever.13 
1.3 MEDICAL AND ECONOMIC IMPACT OF DVT  
In both human and economic terms, DVT and subsequent VTE exact substantial costs. In 2016, the worldwide 
incidence rate of VTE was 115 to 269 per 100, 000, wi th a corresponding worldwide mortality rate of 9.4 to 32.3 per 
100, 000.14 One study found that, in high -income countries in 2014, VTE necessitating hospitalization was the 
second leading  cause of disability -adjusted -life-years lost, which exceeds those lost to adverse drug events and 
nosocomial pneumonia.15 In Europe, VTE is estimated to kill 370 ,000 people every year –  a total greater than that 
caused by AIDS, breast cancer, prostate cancer, and  automobile accidents combined –  and costs the continent 
roughly $3.7 billion annually.8,9,16 In the United States, there are a pproximately 2 million annual cases of DVT, 
which result in about 250 ,000 hospitalizations and 300, 000 deaths – more than those due to myocardial infarction 
or stroke.5,7,8 Even more Americans are at risk for DVT. Since about one quarter of DVT is acquired in the hospital, 
close to 14 million hos pitalized patients are at risk of acquiring it annually.8 All of this co sts between $9 billion and 
$52 billion a year.17 
1.4 DVT  TREATMENT AND CURRENT  SHORTCOMINGS  
The standard of care after an initial DVT episode consists of anticoagulant  treatment for 3 months.3,18,19 For 
patients who have had a second episode, or who have  persisting hypercoagulable comorbidities such as 
malignancy , guidelines recommend extended anticoagulation ( i.e., treatment without a scheduled stopping 
point) .18 Although there is widespread consensus that all proximal DVT should be treated with anticoagulation, 
there is some controversy over whether, and when, it is indicated for isolated distal DVT.3,18-20 
Anticoagulation should only be initiated after DVT has been diagnosed, most commonly by duplex  ultrasound of  
the legs.3,5,21,22 Several different anticoagulants are used to treat DVT. Among these are various preparations of 
heparin – which works by boosting the suppression of factor Xa and thrombin by antithrombin –  and vitamin K 
antagonists (VKAs) such as warfarin.19,21,23 Newer agents called direct oral anticoagulants (DOACs), which inhibit 
either thrombin or factor Xa, are also available.23 American Heart Association DVT treatment guidelines 
recommend 5 days  initial anticoagulation with heparin, as well as concomitant and subsequent administration of a 
VKA, or a DOAC, for longer term anticoagulation.19,23 The American College of Chest Physicians suggests initiating 
therapy with a DOAC rather than a VKA, with or without initial anticoagulation, depending on the specific agent used.
18 
Unfortunately, there are significant limitations associated with the use of anticoagulan ts as sole treatment after 
DVT. Most importantly, although anticoagulation therapy can help prevent new thrombi from forming, it is 
incapable of dissolving preexisting clots, regardless of which specific medication is employed.5 Despite 
anticoagulation therapy, PTS manifests in approximately 50 % of DVT patients within 2 years.24,25 Limitations 
specific to VKAs include a narrow therapeutic index, the need for routine coagulation m onitoring due to patients’ 
genetic variability, which can result in pharmacokinetic and pharmacodynamic heterogeneity, and a large number 
of interactions with foods and other medications.5,23,26 Bleeding events commonly occur in those on 
anticoagulants, the most devastating of which is intracranial bleeding. As well, many oral anticoagulants have 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 12 of 39 
 teratogenic effects, limiting use in pregnancy or during nursing.21,23,27 DOACs, in turn, are contraindicated in 
patients with severe renal failure, and may increase the chance of gastrointestinal bleeding.23 Also, DOACs pose 
unique therapeutic drug monitoring challenges.23 And whereas VKAs can be reversed with vitamin K and 
prothrombin complex concentrate, only one out of the four  DOACs currently approved in the United States is 
reversible.23 
Beyond anticoagulants, other DVT treatment modalities are available. Elastic compression stoc kings – which 
reduce the frequency of PTS – can sometimes be helpful, and the American College of Chest Physicians advises 
that they should be used in most  cases.18,28 However, 21.1 % of patients treated with stockings still go on to 
develop PTS.28 Another treatment option is thrombolytic therapy, in which thrombolytic medications, such as 
tissue -type plasminogen activator, are administered intravenously, in the hope of lysing the clo t, and thereby 
diminishing the risk of PE and PTS.29 But difficulties associated with this approach includ e complications such as 
intracerebral hemorrhage.30 It is also possible to treat DVT via pharmacomechanical thrombolysis, in which 
thrombolytic medication is applied directly into the clot, while the clot is simultaneously excised through 
mechanical means.25 Nevertheless, recent evidence has demonstrated that, relative to standard anticoagulation 
alone, pharmaco -mechanical thrombol ysis does not diminish the risk of PTS, even though it does heighten the 
chance of major hemorrhage.19 For instance, the Acute  Venous Thrombosis: Thrombus Removal with Adjunctive 
Catheter -Directed Thrombolysis (ATTRACT) study randomized  692 patients with acute proximal DVT to receive 
either anticoagulants alone, or anticoagulants  and pharmacomechanical thrombolysis.  The study found that the 
two groups did not differ as to the proportion of patients who developed PTS , whereas the pharmacomechanical 
thrombolysis group had a greater number of major bleeding events within 10 days .27 
1.5 RATIONALE FOR THE CLOTTRIEVER THROMBECTOMY SYSTEM  
Considering  the d rawbacks  of anticoagulation  alone, elastic compression stockings, thrombolytic therapy, and 
pharmacomechanical thrombolysis , patients have the potential  to benefit from a safer and more effe ctive DVT 
treatment, which the Inari  Medical  ClotTriever Thrombectomy System has the potential to provide. The ClotTriever 
is a new treatment option that enables the extraction of extensive thrombi  from large vessels without the need for 
thrombolytic medic ations. It is an over -the-wire system uniquely designed to capture and remove significant 
occluding venous thrombi.  
 
2 STUDY  DEVICE  
2.1 OVERVIEW  
The ClotTriever Thrombectomy System is a single -use over -the-wire catheter -based system . The device  was 
cleared in the US under 510(k) number K163549, February 16, 2017. The device is indicated for the non -surgical 
removal of soft thrombi and emboli from peripheral blood vessels.  
2.2 MANUFACTURER  
Inari Medical  
9 Parker, Suite 100 Irvine, CA 92618 (USA)  
 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 13 of 39 
 2.3 INDICA TIONS FOR USE 
The ClotTriever Thrombectomy System is a single -use over -the-wire catheter -based system for the minimally 
invasive treatment of thromboemboli in the peripheral vasculature.  It is indicated for the non -surgical removal of 
soft thrombi  and emboli from blood vessels, and injection, infusion, and/or aspiration of contrast media and other 
fluids into or from a blood vessel.   
2.4 DEVICE DESCRIPTION  
The ClotTriever Thrombectomy System is comprised of two main components packaged separately:  the ClotTriever  
Sheath (CT Sheath)  and the ClotTriever Catheter (CT Catheter) . 
The CT Sheath provides percutaneous access for the CT Catheter to the treatment site and provides a conduit for 
removal of the CT Catheter and thrombus from the subject after treatment.  Refer to the In structions for Use for 
the device specifications and information.  
3 PRIOR  INVESTIGATIONS  
The Sponsor, Inari Medical (Irvine, CA), developed the study device known as the ClotTr iever Thrombectomy 
System.  The ClotTriever Thrombectomy System was cleared for marketing on February 16, 2017 and has been used 
clinically since that time. Prior to the current study, the ClotTriever Thrombectomy System has not been evaluated 
in a formal clinical study . The current  study will allow the Sponsor to collect patient outcome data on the 
ClotTriever Thr ombectomy System . 
 
4 STUDY  OBJECTIVES  
The primary objective of this study is to evaluate real world  patient outcome s after treatment of acute , subacute,  
and chronic  proximal lower extremity DVT with  the ClotTriever Thrombectomy System . 
Secondary objectives will consist of the following:  
• Assessment of post -thrombotic syndrome, as defined by the Villalta scale31 
• Assessment of symptomatic improvement using the change in venous quality of life indices  
• Determination of p atency (primary, assisted primary, and secondary)  
• Differences in outcome in the acute (≤14 days) , subacute (>14 days ≤6 weeks),  and chronic  (>6 weeks ) 
cohorts and in other subsets  (see Section 10) 
 
  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 14 of 39 
 5 OUTCOME  VARIABLES  
5.1 PRIMARY SAFETY ENDPOINT  DEFINITION  
The primary safety endpoint is the rate of Major Adverse Events (MAE) . MAEs  are defined as a composite endpoint 
triggered when  any of four categories of events through 30 days after the index procedure , as observed in the 
Primary Analysis Safety Cohort : 
• All-cause mortality  
• Major bleeding  
• New s ymptomatic PE documented by CTPA  
• Rethrombosis of a  target venous segment (TVS)  
 
The components of the composite MAE endpoint will be assessed by the independent Medical Monitor.  
5.2 PRIMARY EFFECTIVENESS ENDPOINT  DEFINITION  
The primary effectiveness endpoint is Technical Success , as measured in the Primary Analysis Effectiveness Cohort. 
Technical Success  is defined as complete or near complete (≥75%) removal of venous thrombus  from the TVS. The 
endpoint will be determined volumetrically by the percent reduction in the  Marder score  from baseline (pre -
intervention) venogram to the venogram performed after  use of the study device  but before  the use of other 
adjunctive treatment modalities such as  pharmacologic thrombolysis, other mechanical thrombectomy devices, or 
other intervention with pharmacologic or mechanical means .  Adjunctive therapy is defined as an additional 
thrombus removal strategy after ClotTriever thrombectomy has been completed (i.e.  balloon, stenting, and 
placement of IVC filters during ClotTriever procedure session would NOT be considered adjunctive therapy).  
5.3 SECONDARY ENDPOINTS  
The following secondary endpoints will be studied  in the Primary Analysis Cohorts : 
• Individual components of the MAE composite endpoint  through 30 days  
• Minor bleeding  through 30 days  
• Access site complications from the index procedure (hematoma, false aneurysm, perforation)  through 30 days  
• Device -related death  
• Procedure -related death  
• At any point dur ing follow -up: 
o TVS patency by duplex ultrasound  
o Rethrombosis of the TVS  
o Device -related rethrombosis of the TVS  
o DVT outside of the TVS 
o Target limb edema (edema scale of the rVCSS)  compared to baseline  
o Pain (NPRS) compared to baseline   
o EQ-5D, rVCSS, Villalta scores  compared to baseline  (except discharge)  
 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 15 of 39 
 6 STUDY  DESIGN  
The CLOUT Registry is a prospective, multi- center, observational study of subjects with proximal lower extremity 
DVT treated with the ClotTriever Thrombectomy System. The Registry  will collect data on demographics, 
comorbidities, details from the DVT diagnosis and treatment, and clinical outcomes through 2 -year follow -up. 
Up to 500 subjects with proximal lower extremity DVT will  be enrolled at up to 50 Registry sites.  All subjects who 
sign consent and are treated  with the ClotTriever System  will comprise the Full Analysis dataset . 
The Primary Analysis dataset s will be derived from the 500 subject Full Analysis dataset . Hypothesis testing will be 
performed on this datase t; the safety endpoint testing will be performed on the Primary Analysis Safety cohort  and 
the effectiveness endpoint testing will be performed on the Primary Analysis Effectiveness Cohort . 
• The Primary Analysis Safety cohort will include the first 91 subjects that enroll with a clinical presentation 
analogous to that used for the literature -derived performance goal  (i.e., unilateral acute or  subacute DVT 
of less or equal to  6 weeks ’ duration) . These first 91 subjects will not have been not treated with  
thrombolytic or percutaneous mechanical thrombectomy within the prior 3 months . 
• From these same 91 subjects , the Primary Analysis Effectiveness cohort  will be the subset of subjects who  
undergo treatment with the ClotTriever System in venous segments with  Core Laboratory determined 
intraluminal thrombus.  
 
Once the Primary Analysis cohort  is fully accrued, subjects meeting these criteria will continue to  be enrolled and 
will be evaluated as part of the Full Analysis dataset.  
The primary safety  endpoint will be assessed when the 30 -day follow -up data on the 91 -subject Primary Analy sis 
cohort is complete (see Section 10.4 ), allowing evaluation  of both the primary safety and effectiveness endpoints. 
The remainder of the subjects will be enrolled to  obtain additional safety and effectiveness data and to allow 
subset analyses of various pre -determined subgroups. Subjects in both arms will be followed for 2 years  after the 
index procedure . 
6.1 STUDY POPULATIONS  
The study will consist of up to 500 subjects , i.e., the Full Analysis dataset, who meet the eligibility criteria and are 
appropriate candidates for treatment with the ClotTriever Thrombectomy System. The Primary Analysis dataset is 
a subset of subjects with unilateral acute or  subacute DVT o f less or equal to  6 weeks’ duration, without recent ( ≤3 
months) venous intervention. The first 91 subjects enrolled who meet these criteria will complete the Primary 
Analysis dataset. Enrollment of this type of subject will continue once the Primary Analy sis cohort is fully accrued, 
i.e., past the 91 subjects needed for the primary endpoint analyses. These additional subjects will be included in 
the Full Analysis dataset.  
6.2 INFORMED CONSENT  
Written, study -specific Informed Consent will be obtained from each subject prior to the subject’s deidentified 
medical record or personal health information  (PHI)  being shared with any study representative . The Investigator 
will keep the original Informed Consent Form and a copy will be given to the subject. The subjects will be informed 
that they are free to refuse entry into the study and free to withdraw from the study at any time without prejudice 
to future treatment.  See Section 7.2 for additional information regarding the timing of consent and the point of 
enrollment.   
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 16 of 39 
 6.3 POINT OF ENROLLMENT  
The ClotTriever System is not being used in an investigational manner and the patient will be treated with the 
device in the same manner regardless of whether the patient enrolls in the study . Therefore, the patient’s consent 
for treatment is covered under the institution’s internal procedures. To participate in the study, the patient must 
consent to share his/her deidentified personal health information (PHI)  with the study sponsor. This allow s sites to 
treat patients prospectively and consent patients after treatment. This can be helpful for sites when the research 
staff is unavailable to consent the patient prior to the index procedure (i.e., after hours, weekends, holidays). This 
practice is  allowed provided there is no institutional prohibition against post- procedure consent.  
Pre-procedure consents are the preferred consenting method and should be obtained within  7 days of the 
scheduled index procedure as part of the baseline  work -up. When  post-procedure consents are obtained, the 
consent must be obtained after  the patient gains full capacity after anesthesia and within 7 days of the index 
procedure.  
If the ClotTriever System does not enter the patient’s vasculature, the patient is considered  a screen failure and as 
such, his/her data is not to be entered into the database. A patient is considered enrolled when 1) the device enters the patient and 2) the patient consents to the study. The timing of the two events, index procedure and consent, are interchangeable.  
6.4 INCLUSION CRITERIA  
Subjects may be enrolled in the study if they meet all the following : 
6.4.1 Age ≥ 18 years  
6.4.2 Proximal lower extremity DVT involving the femoral, common femoral, iliac veins or inferior vena cava 
(IVC), alone or in combinationa 
6.4.3 Willing and able to provide  informed consent  
6.5 EXCLUSION CRITERIA  
Subjects  will be excluded from the study for any of the following : 
6.5.1 Prior v enous stent in a TVS 
6.5.2 IVC aplasia/hypoplasia  or other congenital anatomic anomalies of the IVC or iliac veins  
6.5.3 IVC filter in place when ClotTriever system enters  the patient (Patients can be included if an existing IVC 
filer is removed prior to insertion of the ClotTriever system ) 
6.5.4 Allergy, hypersensitivity, or thrombocytopenia f rom heparin or iodinated contrast agents, except for mild 
to moderate contrast allergies for which pretreatment can be used  
6.5.5 Life expectancy less than 1 year  
6.5.6 Chronic non -ambulatory status  
6.5.7 Known hypercoagulable states that, in the opinion of the Investigator, c annot be medically -managed 
throughout the study period  
 
a Subjects with bilateral DVT may be enrolled but will not be included in the Primary Analysis Dataset.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 17 of 39 
 6.5.8 Unavailability of a proximal lower extremity venous access siteb 
7 ASSESSMENTS  AND  FOLLOW -UP SCHEDULE  
7.1 SCHEDULE OF ASSESSMENTS  
The data collected will be standard -of-care. In this regard, the Schedule of Assessments comprises recommended 
evaluations, and any departures from the schedule will not be considered Protocol Deviations  (see Section 11.3) . 
Table 1. Schedule of Assessments  
  
 
b For example, from a popliteal, femoral or other infrainguinal vein on either side. Jugular access is not allowed.  Assessment  Baseline *      
(-7 to 0 days)  Index 
Procedure  
(day 0)  Discharge  30 Days  
(14 to 45 days)  6 Months  
(46 to 270 days)  1 Year  
(271 to 540 days)  2 Years  
(541 to 900 days)  Unscheduled 
Visits  
Medical  history  X        
Physical examination†  X  X X X X X X 
Inclusion/exclusion criteria  X        
Anticoagulation regimen  X X X X X X X X 
Duplex ultrasound§ X   X X X X X 
Venogram  (Required)   2x+       
IVUS  (Expected)   2x+       
Access site e xamination    X X     
Adverse event  assessment   X X X X X X X 
CEAP Score║ X        
EQ-5D, Villalta, rVCSS  Quality 
of Life Assessments  X   X X X X  
Edema and Numeric Pain 
Rating Scale (NPRS)  
assessment  X  X X X X X  
*Baseline  assessments must be performed no more than 7 days prior to the index procedure or after the onset of symptoms in those subjec ts with 
less than 7 days’ symptom duration. 
†Physical examination is limited to the involved lower extremity(ies). Examination wil l include an assessment of leg edema, graded as per the rVCSS 
scale; mild (limited to foot and ankle), moderate (above ankle but below knee), or severe (knee and above), and recorded on t he right and left legs. 
§Duplex ultrasound will include patency assessments of all target lesions including flow (present , absent, or not evaluable ) and compressibility 
(normal, partial, incompressible, not evaluable ). 
+ Imaging will be captured before C lotTriever  treatment and after C lotTriever  treatment but before adjunctive therapy (if any). If adjunctive therapy is 
utilized, a third set of images will be obtained afterwards. In addition, if a reintervention is performed, the same imaging timing and transfer are 
required.  Note that adjunctive  therapy is defined as an additional thrombus removal strategy after ClotTriever thrombectomy has been completed 
(i.e. balloon, stenting, and placement of IVC filters during ClotTriever procedure session would NOT be considered adjunctive  therapy).  
║CEAP (Clinical, Etiologic , Anatomic , and Pathophysiologic ) score is a clinical classification score developed to allow uniform diagnosis and 
stratification of patient populations according to the severity of their presentation  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 18 of 39 
 7.2 BASELINE ASSESSMENT  
The Baseline Assessment  includes diagnostic testing , patient status, and eligibility verification for study 
participation  including : 
• Review inclusion/exclusion to ensure patient meets criteria  
• Review duration of symptoms  
• Confirm venous  thrombus presence on duplex ultrasound  
 
If the patient meets all eligibility  criteria and is scheduled  for the thrombectomy  procedure , the patient may be 
invited to participate in the study.  
The data captured for the Baseline  Visit may be gathered over the course o f more than one office visit; however, 
the data must have been obtained within  7 days  of the scheduled index procedure date  and, for subjects with 
symptoms of less than 7 days’ duration , after  the onset of symptoms . 
The following procedures will be performed at  Baseline  prior to the index procedure . All data must be recorded in 
the subject’s case report form s (CRF): 
• Demographic information  
• Medical history including risk factors  
• Physical examination  including an edema evaluation of both legsc 
• Presence of relative and absolute contradictions to pharmacologic thrombolysis  
• Anticoagulation Regimen  
• Duplex ultrasound assessment of  patency of the TVS 
• CEAP Score  
• EQ-5D, Villalta , rVCSS,  
• Edema and Numeric Pain Rating Scale (NPRS)  
 
Clinical laboratory tests are expected to be performed at this visit to establish baseline levels  (i.e., creatinine, 
platelet counts , and INR if  subject  is on warfarin) . The panel of tests standardly performed at the institution for 
patients with similar c onditions  related to DVT should be considered . It is recognized that specific panels may vary 
between institutions. Laboratory data will not be specially analyzed but will be used to support adverse event (AE) 
evaluations.  
Subjects with bilateral DVT may b e enrolled. Each leg’s TVS will be counted separately in the 500- subject Full 
Analysis  dataset. The second leg may only be enrolled and treated at the time of the primary leg’s index 
procedure . 
 
c Measurements are to be taken from th ree locations: (1) Thigh = midpoint between the hip and the proximal edge of the patella; (2) Mid -Calf = 
midpoint between the tibial tuberosity and the medial malleolus; and (3) Ankle = 2 cm about the medial malleolus.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 19 of 39 
 7.3 INDEX PROCEDURE  
Thrombectomy  using the ClotTriever  System  is considered the index procedure and the treatment phase of the 
study.  The procedure is conducted under fluoroscopic/angiographic guidance. Refer to the Instructions for Use 
(IFU) for techniques and methods for device deployment.  
Anticoagulation th erapy to ensure an activated clotting time of 250 –  300 seconds is recommended.  
Subjects who require conversion to open surgery due to treatment failure with the device will be followed  for 
safety  through 30 days , or until any treatment related adverse events resolve , which eve r is later . 
The following data are to be recorded on the subject’s Procedure  CRF.  
• Length of procedure  (from ClotTriever sheath access to last removal of sheath ) 
• Number of ClotTriever  passes  
• Number of ClotTriever devices used , with lot numbers  
• Largest s heath size used  
• Pre- and post -procedure venogram  findings  
• Pre- and post -procedure IVUS  measurements  
• Concurrent use of balloon angioplasty and /or stenting  and/or placement of IVC Filter  
• Adjunctive  therapy  (thrombolysis and /or additional  thrombectomy) .  
• Anticoagulant used and amount  
Venogram runs/cines must be , and IVUS  runs should be , acquired pre -ClotTriever and post -ClotTrieverd.  If 
adjunctive therapy is used, a third venogram  and IVUS run  post -therapy will be acquired . All procedural venogram s 
cines and IVUS images will be de -identified, labeled appropriately, uploaded  and sent  to the Core Laboratory . 
7.4 TARGET VESSEL SEGMENT (TVS)  ASSIGNMENT  
The target vessel segment (TVS)  is thrombus -containing venous segments, specified by the operator, that were 
treated with the  study device at the index procedure. These segments may include the popliteal vein, caudal 
femoral vein, cranial femoral vein, profunda/deep femoral vein, common  
femoral vein, external iliac vein, inter nal iliac vein, common iliac vein, or the inferior vena cava . The TVS does not 
include segments that were not intentionally treated but were instead passed through to remove the device from 
the leg.  
All vessels treated in one leg /side  are recorded under on e TVS.  There are three possible TVS designati ons: 
• For unilateral treatment: TVS 1 = Leg 1 and can be any or all segments from the IVC to the pop liteal  
• For bilateral treatment only : TVS 2 = Leg 2 and will not include the IVC (if the IVC was treated, record it as 
part of TVS 1)  
• For IVC treatment only : Neither leg was treated,  and the treatment was IVC only  (designate as TVS 1)  
 
d Ballooning and/or stenting  and/or I VC placement  during the procedure is routine and not considered adjunctive therapy. Adjunctive therapy includes thrombolysis and additiona l thrombectomy.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 20 of 39 
 7.5 CLINIC/HOSPITAL  DISCHARGE  ASSESSMENT  
Subjects will be evaluated dur ing the time after procedure completion and prior to clinic/ hospital release. The 
following information will be collected on the Discharge CRF:  
• Time spent in ICU and hospital  
• Physical examination  of the target proximal lower extremity(ies) , including an edema evaluation of both legs  
• Anticoagulation regimen  
• Examination of access site for wound comp lications  
• Rethrombosis since leaving the procedure room  
• Reintervention since leaving the procedure room  
• AE observations  
• Blood transfusions  
• Edema and Numeric Pain Rating Scale (NPRS)  
Thrombus removal interventions that are performed at the end of the index procedure prior to the subject leaving 
the procedure room will be reported as adjunctive procedures and  are not tabulated as reinterventions. In 
addition, before the subject has left the procedure room , formation of thrombus within  the treated TVS is not 
reported as a rethrombosis when it occurs during the index procedure.  
7.6 FOLLOW -UP ASSESSMENT S AND WINDOWS  
Follow -up evaluation will be scheduled at 30 days  (14-45 days), 6 months (46 -270 days), 1 year (271- 540 days), and 
2 years  (541- 900 days) post -procedure. The following assessments and procedures will be performed at each  
follow -up visit:  
• Physical examination of the target  proximal lower extremity( ies), including an edema evaluation of both legs  
• Anticoagulation regimen  
• Duplex ultrasound of TVS for patencye 
• Rethrombosis since the last visit  
• Reinterventions since the last visit  
• AE observations  that occurred since the last visit  
• Quality of life indices  (EQ-5D, Villalta, and rVCSS)  
• Edema and Numeric Pain Rating Scale (NPRS)  
 
7.7 PROCEDURES , REINTERVENTIONS , AND RETHROMBOSIS  
After  the index procedure , conditions warranting additional treatment may present. Any intervention taken to 
treat a condition involving the initially treated  TVS shall be documented.   Adjunctive therapy is defined as an 
 
e Duplex ultrasound will also be performed at unscheduled visits when the reason for the visit was pot entially a patency -related event.  The 
duplex ultrasound examination will specify whether each TVS was a) normal (compressible with flow), b) abnormal but patent (partially 
compressible with flow), or c) occluded (absent flow or incompressible). In the pre sence of a double femoral vein and when only one of the 
veins was treated, the sonographer must be certain to perform the duplex ultrasound assessment on the treated vein.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 21 of 39 
 additional thrombus removal strategy after ClotTriever thrombectomy has been completed (i.e. balloon, stenting, 
and placement of IVC filters during ClotTriever procedure session would NOT be considered adjunctive therapy).  
If a subject requires TVS venography during the follow -up period, the images  must be sent to the core laboratory 
for analysis. For any TVS reintervention, pre - and post- reintervention images must also be sent.  
7.8 UNSCHEDULED FOLLOW -UP VISITS 
This Registry study was designed to capture real -world data regarding the clinical use of the  ClotTriever 
Thrombectomy System.  Therefore, the study w ill only  record subject visits during the follow -up period that are 
related to the subject’s DVT condition and treatment.  If a subject returns to the site  between scheduled follow -up 
visits for matter s related  to the study , the visit will be treated as an unscheduled visit and the assessments 
completed at this visit will be done at the discretion of the Investigator . CRF pages are provided for unscheduled 
visits and contain the same information as all the follow -up visits, in addition to the reason for the visit.  
7.9 WITHDRAWALS AND LOST TO FOLLOW -UP 
Participation is completely voluntary,  and each subject is free to withdraw from the study at any time. An 
investigator also has the right to withdraw the subject from the study in the event of reasons concerning the 
health or well -being of the subject, or in the case of lack of cooperation. S hould a subject decide to withdraw for 
any reason, or should the investigator decide to withdraw the subject, all efforts will be made to complete and 
report the observations up to the time of withdrawal as thoroughly as possible. A complete final evaluati on at the 
time of the subject’s withdrawal must  be made and an explanation given as to why the subject is withdrawing or 
being withdrawn from the study.  
The reason for and date of withdrawal must be recorded on the subject’s End of Study /Study Exit  CRF. If  the 
reason for the withdrawal is a device -related  or procedure related AE , the event must be reported to the S ponsor 
and recorded in the CRF.  
If the procedure is aborted,  the subject does not need to complete the follow -up assessments , unless the subject is 
converted to surgical repair.  Subjects who require conversion to open surgery due to treatment failure with the 
device will be followed  for safety  through 30 days, or until any treatment related adverse events resolve, which 
ever is later.  The subject’s  enrollment roster position may not be made available to other subjects  (i.e., the subject 
will not be replaced) . 
All efforts will be made to return subjects for all the follow -up visits . Due diligence in reaching the subject must  be 
made by  two documented telephone contact  attempts , emails , or regular postal mail letters . After the above 
attempts are made, if no response is obtained, the final evaluation of the subject will be the last vis it at which 
study -related procedures were performe d. The End of Study /Study Exit CRF page will be completed,  and 
communication attempts will be documented.  
7.10 COVID -19 EFFECT  ON RESEARCH  
This Registry study was designed to capture real -world data regarding the clinical use of the ClotTriever System. As 
a result of the COVID -19 pandemic, clinic practice patterns may have been affected and patient visits may have 
been postponed or eliminated .  In addition, some data may be collected from patients over the phone .  Our goal is 
to collect as much real -world data as possible while protecting everyone’s safety. In light of this situation, any 
deviation from the protocol due to COVID -19 will not be  recorded as a protocol deviation (see Section 11.3 for 
additional information regarding protocol deviations).  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 22 of 39 
  
8 RISK  ANALYSIS  
8.1 RISKS TO THE SUBJECTS  
The CLOUT Registry involves the use and disclosure of deidentified personal health information. It collects only 
information relevant to the subject’s DVT  condition and its treatment.  
The Registry study involves the collection of specific information for research and educational purposes only. It 
does not specify how the ClotTriever Thrombectomy System will be used to treat thrombus, and decisions 
regarding a subject’s treatment are not influenced by the Registry  study . Physicians participating in the Registry  
study  are expected to review the indications, contraindications, warnings, precautions, and AEs describ ed in the 
IFU. As with any endovascular procedure, the treating physician is expected to counsel the subject on the risks and 
benefits specific to the planned treatment and to obtain procedure -related informed consent per institutional 
policy and procedure . 
8.2 RISK MITIGATION  
This Registry study was designed to capture real -world data regarding the clinical use of the ClotTriever 
Thrombectomy System. The risk of providing this personal health information is believed to be minimal, as 
information directly identifying the subject will not be collected for the Registry database.  All data handling will be 
in accordance with HIPAA requirements and only deidentified PHI will be used . 
 
9 SAFETY ASSESSMENTS  
9.1 DEFINING ADVERSE EVENTS  
An AE is an untoward medical occurrence or exacerbation of an existing medical condition subsequent to  
treatment with the ClotTriever . AEs are classified  in several ways , including  severity, relationship, and seriousness.  
•  Severity (mild, moderate, severe)  
- Mild : No limitation of usual activities, no therapy or only symptomatic therapy required to treat the 
injury or illness.  
- Moderate : Some limitation of usual activities or specific therapy is required.  
- Severe : Inability to carry out usual activities, hospital ization, emergency treatment, life threatening 
events, or death.  
• Relationships (unrelated, device -related, procedure -related, or relationship unknown)  
- Unrelated:  The clinical event is completely independent of study procedure/study device and/or 
evidence  exists that the event is definitely related to another etiology.  
- Device-related:  An event that can be directly attributed  to the use of the device, wherein, if the device 
functioned 100% to specifications and expectations, the event would not have occurred.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 23 of 39 
 o Rethrombosis in the absence of device induced vascular trauma (documented on an imaging 
study or with direct visualiza tion of the vessel) is not device -related; rather it is a complication 
related to ineffective anticoagulation therapy.   
o Perforation from the study device is device -related, but perforation from a non-study adjunctive  
device is not.  
o As well, events that o ccur as a result of downstream venous compression (e.g., May -Thurner 
syndrome) are not considered device -related.  
- Procedur e-related:  An event that is not device -related and occurs as a result of the procedure.  
o Events that  occur ≤30 days  of the index pro cedure or ≤ 30 days of a secondary procedure 
performed for a previous procedure -related complication, if the event is not device -related.  
o Examples include complications from ineffective anticoagulation (e.g. rethrombosis), excessive 
anticoagulation (e.g. bl eeding), or vascular access with a non -study device (e.g. generic sheath, 
guidewire injury); distant complications (e.g. myocardial infarction, pneumonia); or contrast-
induced complications (e.g. contrast -induced nephropathy or hypersensitivity reaction).  
- Relationship unknown : The relationship to the study procedure/study device is not known.  
• Seriousness (serious, non -serious)  
- Serious AE (SAE) : An event that meets at least one of the following:  
Is fatal  or life-threatening Results in persistent or significant disability/incapacityResults in permanent 
impairment of a body function or permanent damage to a body structure  
Results in hospitalization or prolongs a hospitalization  and necessitates medical or surgical 
intervention to preclude  permanent impairment of a body function or permanent damage to a body 
structure  
9.2 REPORTING ADVERSE EVENTS  
The CLOUT Registry s tudy was designed to capture real-world data regarding the clinical use of the ClotTriever 
System and involves the collection of specific information for research and educational purposes only. It does not 
specify how the ClotTriever Thrombectomy System will be used to treat DVT , and decis ions regarding a subject’s 
treatment are not influenced by the study. This is a data collection study only; there is nothing investigational or 
experimental in the subject’s medical treatment.  
Therefore, the study will only  capture  AEs related to the subje ct’s DVT condition and its treatment. Reportable AEs 
include all  events considered in the safety analyses  (i.e.,  major or minor bleeding, access site complications, new 
symptomatic PE within 30 days,  or rethrombosis ), all device - and/or procedure -related AEs, as well as any event 
resulting in death .  
The AEs will be captured on the Adverse Event CRF and should include, wherever possible, severity, duration, 
outcome, and the Investigator’s description of the event and his/her medical judgment as to the relationship of 
the AE (i.e., not related, related, or relationship unknown)  to the study device, the ind ex procedure  or any 
subsequent procedure (s), to a thrombolytic agent or anticoagulant, or to underlying disease.  
• Non-serious reportable AEs are to be submitted via the electronic data capture system  (EDC)  in a timely 
fashion.  
• Reportable SAEs must be reported to the Sponsor within 5 business days of the Investigator’s knowledge 
of the event. The event is reported in the electronic data capture system.  
 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 24 of 39 
 Appendix 1  includes a list of possible SAEs associated with thrombectomy , including those events considered major 
device -related events and major morbidity. These events are considered reportable at all time points throughout 
the study and require submission to the Sponsor.  
 
10 STATISTICS  AND  DATA  ANALYSIS  
10.1 STATISTICAL METHODOLOGY  
The statistical design o bjective for this study is to evaluate patient outcomes of the study device, as assessed in 
comparison to literature -derived performance goals.  
The safety and effectiveness performance goals were determined from a literature review of publications on the 
treatment of DVT. A total of seven studies were included in this review and, among these, all publications reported 
data referable to the primary safety endpoint and six of the seven publications reported data referable to the primary effectiveness endpoint . Studies with populations that overlapped the population of another study were 
excluded. In general, these studies report data on acute and subacute DVT, but not chronic.  
10.2 PRIMARY SAFETY ENDPOINT ANALYSIS  
The primary safety endpoint for this study will be assessed in the Primary Analysis  Safety  cohort  and is a composite 
endpoint of any MAE within 30 days, as determined by the independent Medical Monitor. The MAE is defined as  the 
30-day rate of all -cause mortality, major bleeding, new symptomatic PE documen ted by CTPA, or rethrombosis of 
the target venous segment (s). The rate of MAE will be compared  to a performance goal with the following null and 
alternative hypotheses:  
H0:  P S ≥ PG S versus H A: PS < PG S 
where Ps is the proportion of subjects free from MAE through 30 days and PG S is the safety performance goal 
derived from the studies reporting the elements contained in the composite MAE endpoint.  
The exact binomial one -sided 97.5% confidence interval will be used to test the primary safety endpoint.  
10.3 PRIMARY EFFECTIVENESS ENDPOINT ANALYSIS  
The primary effectiveness endpoint is Technical Success, defined by complete or near complete thrombus removal. Thrombus removal is determined by the Marder score at the index procedure, measured after use of the study 
device but prior to the use of adjunctive devices. Effectiveness will be assessed in the Primary Analysis 
Effectiveness Cohort
f and will be compared to a performance goal with the following null and alternative 
hypotheses:  
H0:  PE ≤ PG E versus H A: PE > PG E 
where P E is the proportion of subjects with Technical Success, as defined complete or near complete removal of 
thrombus with the study device, defined by venographically -determined reduction of ≥75% in the Marder score in 
 
f This dataset wa s designed to exclude those subjects treated who underwent venous thrombectomy for lesions that were non -thrombotic in nature. For instance, those with non -thrombotic May -Thurner lesions that have external 
compression or scar but who do not have demonstrable intraluminal thrombus. These subjects will remain in the Primary  Safety Cohort  and will be assessed for safety endpoints but will not be assessed for the effectiveness 
endpoints.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 25 of 39 
 the TVSs. The effectiveness perf ormance goal, PG E, is Technical Success defined in the same manner, derived from 
the published literature.  
10.4 STUDY SUCCESS CRITERIA  
The study will be considered a success if both primary endpoints meet their respective performance goals. For the 
safety endpo int, this translates into observing a one -sided 97.5% lower confidence limit (LCL) of the point estimate 
below 34% and for the effectiveness endpoint,  it means observing a one -sided 97.5% LCL above 30%.  
10.5 MISSING DATA 
Every effort will be made to minimize the amount of missing data. Recognizing the difficulty of avoiding some 
missing data, however, data imputation methods with sensitivity imputation analyses will be specified in the 
Statistical Analysis Plan. Subjects with missing effectiveness data will be assumed to have missing data at random 
and will be imputed by random selection with replacement of data from subjects with pre - and post -intervention 
measurement of thrombus removal. The robustness of the multiple imputation outcome will be teste d with a 
tipping point analysis encompassing all possible imputation outcomes.  
10.6 SAFETY PERFORMANCE GOAL DERIVATION  
The primary safety endpoint of 30 -day MAE was assessed from published studies that treated DVT with 
pharmacologic means or with other thrombec tomy devices .  The weighted average MAE rate was 23.8%. Using a 
10% margin and rounding to the nearest percent, the performance goal for the primary safety endpoint, 30 -day 
freedom from MAE, was  34%.  A detailed analysis of the safety performance goal will be described in the statistical 
analysis plan.  
10.7 EFFECTIVENESS PERFORMANCE GOAL  DERIVATION  
The primary effectiveness endpoint of Technical Success was assessed from published studies that treated DVT 
with pharmacologic means or with other thrombectomy device s). The weighted average Technical Success rate 
was 39.3%. Using a 10% margin and rounding to the next percent, the performance goal for the primary effectiveness endpoint of Technical Success was 30%.   A detailed analysis of the effectiveness performance goal 
will be described in the statistical analysis plan.  
10.8 SAMPLE SIZE 
The performance goal of 34% has been established for the primary safety endpoint, based on a one -sided 97.5% 
exact binomial test. The 30 -day MAE rate is anticipated to be approximately 20 %. Under this assumption, the 
required sample size to achieve a level of 82% power is 86 subjects ( Table 2). Assuming 5% attrition over 30 days, 
enrollment of 91 subjects is necessary for the Primary Analytic Dataset.  
Table 2. Sample Size - Primary Safety Endpoint  
Measure  
Performance goal  34% 
Anticipated freedom from MAE  20% 
Significance level  .025  
Statistical test  One-sided exact binomial test  
Desired power level  82% 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 26 of 39 
 Required sample size prior to 5% 30 -day attrition rate  86 
Required sample size after attrition adjustment  91 
 
A performance goal of 30% has been established for the primary effectiveness  endpoint. Anticipating an actual 
Technical Success rate of approximately 50%, and based upon a one -sided 97.5% exact binominal test, the 
required sample size to achieve a level of 97% power is 85 subjects ( Table 3). Since the primary effectiveness 
endpoint is determined at the time of the index procedure, no attrition has been considered for lost to follow -up 
or other censoring events. Howe ver, the effectiveness endpoint is evaluated in the Primary Analytic Effectiveness 
cohort , and it is assumed that 3% of enrolled subjects will be treated for DVT in the absence of core laboratory -
assessed visible thrombus in the TVS. Assuming a 3% attritio n rate for subjects without thrombus, enrollment of 88 
subjects will be necessary.  
Table 3. Sample Size - Primary Effectiveness Endpoint  
Measure  
Performance goal  30% 
Anticipated technical success rate  50% 
Significance level  .025  
Statistical test  One-sided exact binomial test  
Desired power level  97% 
Required sample size prior to 3% attrition for subjects without thrombus  85 
Required sample size after attrition adjustment  88 
 The required sample size is greater for the primary safety endpoint; 91 vs. 88 subjects. Thus, a total of 91 subjects 
will be enrolled in the Primary Analysis dataset ; providing approximately 91  subjects in the Primary Safety cohort  
and 88 subjects in the Primary Effectiveness cohort  for the primary safety and effectiveness analyses, respectively. 
The overall power of the study is 80%.  
10.9 CONTINUED ENROLLMENT BEYOND THE PRIMARY ANALY SIS DATASET  
Once the required number of subjects  for the Primary Analysis data set are enrolled, subject enrollment will 
continue in the Full Analysis dataset . In total, 500 subjects will be enrolled in the study , with a subset of  91 subjects 
in the Primary Analysis  Dataset . The aggregate Full Analysis dataset will comprise the 91  Primary Analysis  cohort 
and the 409 subjects not in that cohort. Enrollment of the 500 subject aggregate Full Analysis  population will allow 
descriptive safety and effectiveness analyses on a larger dataset than would the Primary Analysis  dataset alone, 
with subgroup analyses as described in S ection 10.11.  
Subjects who do not fit the criteria for the Primary Analysis Dataset will be enrolled in the Full Analysis Cohort in 
parallel (see S ection 6.4). It is likely that the Primary Analysis Cohort will be enrolled before 409 subjects have been 
enrolled in the F ull Analysis Cohort. O nce enrollment in the Primary Analysis Cohort is fully accrued,  subjects that 
subjects that would have met the criteria for inclusion into this subset will continue to be enrolled as part of  the 
Full Analysis dataset . 
10.10  DEMOGRAPHICS AND  BASELINE CHARACTERISTICS  
The baseline demographics and anatomic characteristics of the treatment group will be presented with descriptive statistics.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 27 of 39 
 10.11  SUBGROUP AND OTHER ANALYSES  
The following subgroups will be analyzed:  
• Acute  (≤14 days)  versus  subacute (>14 days ≤6 weeks)  versus chronic  (>6 weeks ) 
• Iliofemoral versus femoropopliteal  
• Men versus women  
• Old versus younger (≥65 years, <65 years)  
• Obese versus not obese (BMI ≥30 kg/m2, >30 kg/m2) 
 
10.12  DATA POOLABILITY  ASSESSMENT  
Poolability of data across clinical study sites is justified on a clinical basis (i.e. all study sites use the same protocol), 
the Sponsor monitors the site for protocol compliance, and the data gathering instruments are identical. The FDA 
also requires a statistical assessme nt of poolability. This is done by comparing the baseline characteristics across 
study sites. For categorical baseline variables, such as sex, a generalized Fisher’s exact test or equivalent test will be used and for quantitative variables, parametric or n on-parametric analysis of variance (general linear models or 
an equivalent procedure) will be used.  
The above statistical analyses do not result in an impediment to pooling, but rather assess the balance of baseline 
covariates across study sites. If any ba seline covariate is found to be statistically significant by this process, 
generalized linear mixed model (GLMM) will be used to assess site heterogeneity . This is done by using site a 
random effect and further quantifying the heterogeneity in terms of Hig gin & Thompson’s I
2 index . 
It may be necessary to combine two or more low enrolling study sites into pseudo -sites to allow these analyses. 
Sites with fewer than six subjects will be ranked by enrollment from low to high. Starting from the lowest enrollment  site, sites will be combined into a pseudo site until the combined size reaches the median enrollment 
among all sites. This process will be repeated until all resulting sites have enrollment equal to or greater than six subjects. This will be done in a ma nner to preserve the structure of the study and prevent bias.  
Baseline characteristics to be considered as possible covariates will include:  
• Age 
• Sex 
• Coronary artery disease  
• Chronic obstructive pulmonary disease  
• Myocardial infarction  
• Hyperlipidemia  
• Cerebro vascular accident  
• Hypertension  
• Diabetes  
• History of tobacco use  
• Duration of symptoms  
• Isolated iliofemoral DVT versus iliofemoral and distal DVT  
• History of hypercoagulable state  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 28 of 39 
 • Obesity  
 
If there are relatively few missing data points (e.g., <10%) for a given variable, a simple imputation using the mean 
(for continuous variables) or median (for dichotomous or categorical variables) of the non -missing values will be 
done. If there are >10% missing, the variable will be excluded from the imputation analysis . 
Poolability analysis will also be performed on the primary endpoints comparing across sites after adjusting for 
covariates difference. Logistic regression model will be utilized to include unbalanced covariates and site as an 
independent variable, and th e study outcome as dependent variable to assess outcome difference. If the p -value 
of site effect is less than 0.10, further analyses will be undertaken to investigate the imbalance of the study outcome.  
11 STUDY  MANAGEMENT  CONSIDERATIONS  
11.1 DATA MANAGEMENT : CLINICAL DATA 
The Sponsor  and/or  designee  will be responsible  for the processing  and quality  control  of the data. All source 
data, CRFs, copies of protocols and protocol amendments, correspondence, subject identification lists, informed consent forms, and other essential documents must also be retained for a period of at least 2 years after  study  
completion  or closure . 
No study  document  or image  will be destroyed without prior  written  agreement between  the Sponsor  and the 
Investigator  prior to conclusion of  the retention period  (see Section 12.4.2) . Should the Investigator  wish  to assign  
the study records to another party or move them  to another location, advance written  notice  must  be given  to the 
Sponsor.  
11.2 PROTOCOL MODIFICATIONS  
No changes from the final approved protocol will be initiated without the IRB’s prior written approval of the  
amendment. The Principal Investigator will acknowledge an amendment by signing the Protocol Signature Page . 
11.3 PROTOCOL DEVIATIONS  
A protocol deviati on is the non -adherence to or divergence from the protocol -specific required study procedures. 
For example, violations of the inclusion and exclusion criteria, improper or lack of consent, and lack of IRB approval, would all be considered protocol deviations.
g  
Given that this is a registry study capturing real -world data  and standard of care may differ amongst sites, 
deviations from the protocol with regards to specific pro cedures , testing,  and data points  collected , as well as visit 
windows , will not be captured as a protocol deviation. However, the Sponsor will address any trends  in omissions 
and deviations observed and work with the investigational site  to improve data collection where possible.  
 
g Subject eligibility for the study is determined by site -measured anatomic criteria, not by core laboratory values. For this reason, core 
laboratory -determined anatomic measurements from the baseline, pre- interventional angiogram are not part of subject eligibility 
determination and are not considered protocol deviations.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 29 of 39 
 A record of reportable protocol deviations , as described above,  will be maintained,  and reviewed throughout the 
conduct of the study. The Sponsor will address deviations and take appropriate corresponding action. Continued 
non-compliance with the study protocol may lead to termination of the Investiga tor’s participation in the study.  
11.4 INFORMATION TO STUDY PERSONNEL  
The Investigator is responsible for giving information about the study to all staff members involved in the study or in any element of subject management, both before starting the study and d uring the course of the study (e.g., 
when new staff become involved). The Investigator must ensure that all study staff members are qualified by education, experience, and training to perform their specific responsibilities.  
The Sponsor or designee  is resp onsible for explaining the protocol to all study staff, including the Investigator, and 
for ensuring their compliance with the protocol throughout the study. Additional information will be made available during the study when new staff become involved in the study, and as otherwise agreed upon with either 
the Investigator or the Sponsor or designee . 
 
12 STUDY  ADMINISTRATION  
12.1 SITE INITIATION  
A Site Initiation Visit (SIV) will  be conducted by the Sponsor or designee in-person or via teleconference to ensure 
proper training of the Investigator and study staff members regarding the study protocol and data collection, as 
well as to ensure regulatory requirements are fulfilled prior to enrollment of the first study subjec t at a site.  
12.2 STUDY MONITORING  
Interim monitoring visits may  be conducted by the Sponsor or  designee in-person or remotely to ensure 
compliance with  the protocol, and other written instructions and regulatory guidelines  according to the study -
specific monitoring plan.  
The main responsibilities of the M onitor are to ensure adherence to the protocol; to verify all data are correctly 
and completely recorded and reported; and confirm that informed consent is obtained and rec orded for each 
subject before any medical record or personal health information is shared with any study representatives . The 
Investigator and assisting staff must agree to cooperate with the M onitor  or Sponsor repre sentative  to resolve any 
study -related problems, errors, or possible misunderstandings concerning the findings detected during  these 
monitoring visits  or data review . 
12.3 STUDY TERMINATION  
Inari Medical and applicable regulatory authorities have the right to terminate the entire study  or a specific study  
site at any time. Situations that could warrant study termination include, but are not limited to:  
• Increased incidence of adverse experiences and/or the severity of such, suggestive of a potential, device -
related health hazard  
• Insuffic ient subject enrollment  
• Recurrent protocol non -compliance, violations,  or deviations  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 30 of 39 
 • Inaccurate, incomplete, and/or untimely data recording or query responses (> 5 business days) on a 
recurrent basis  
• Lack of cooperation with monitoring visits (e.g., failure  to adequately prepare for visits, address action items 
from one visit to the next, or provide access to medical records)  
12.4 DATA HANDLING AND RECORDKEEPING  
12.4.1 Completing, Signing and Archiving Case Report Forms  
Clinical study data will be collected using electronic case report forms (eCRFs). A web -based electronic data 
capture (EDC) database will be used to record and manage study data. eCRF completion guidelines, the 
instructions for electronic data -entry will b e developed in conjunction with the Sponsor  and/or the EDC vendor. All 
eCRFs must be kept in good order and updated so they always reflect the latest observations on the subjects participating in the study.  
The Investigator will sign the appropriate eCRF pages and source documentation. Pertinent eCRF corrections will 
be made electronically and signed electronically by the Investigator. An embedded audit trail will capture the date, 
time and user making updates and changes to the electronic data.  
Because it is important to have proper data collection in a timely manner, within 5  business days  of the study 
visit/assessment , the Investigator/Study Coordinator shall complete the eCRFs. When the  Sponsor  or designee  
requests additional data or clarification of data for the eCRF, the request must be answered satisfactorily in a timely manner . 
12.4.2 Data Management and Archiving  
The Sponsor will be responsible for the processing and quality control of the data. All source data, eCRFs, copies of 
protocols and protocol amend ments, correspondence, subject identification lists  (kept by the Investigator) , 
informed consent forms, and other essential documents must be retained for a period of at least 2 years after the study completion  or closure .  
No study document or image will be destroyed without prior written agreement between the Sponsor and the 
Investigator. Should the Investigator wish to assign the study records to another party or move them to another 
location, advance written notice must  be given to the Sponsor.  
12.4.3 Direct A ccess to Source Data/Documentation  
The Investigator must maintain, at all times, the primary records, (i.e., the original source of data/ source 
documents) of each subject’s data. Examples of source documents are hospital records, office visit records, 
exam ining physician’s findings or progress notes, consultant’s written opinion or notes, laboratory reports, imaging 
data, and CRFs that are used as the source.  
The Investigator may  keep a separate subject identification list showing enrollment numbers, names,  and dates of 
birth to allow unambiguous identification of each subject included in the study.  It is recommended a note be made in the medical record that the subject is participating in a clinical research study.    
The Sponsor, auditors, and health autho rity inspectors (or their agents) will be given direct access to source data 
and documentation (e.g., medical chart/records, laboratory test results, images ) for source data verification, 
provided that subject confidentiality is maintained in accordance wi th local requirements.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 31 of 39 
  
13 ETHICS  
13.1 INFORMED CONSENT  
Written informed consent will  be obtained from  each subject prior to the subject’s medical record or personal 
health information being shared with any study representative .  The subject’s willingness to participate in the 
study will be documented in writing in a study -specific Informed Consent Form, which will be signed and dated by 
the subject or Legally Authorized Representative.  The Investigator will keep the original consent form and a copy 
will be given to the subject.  It will be explained to the subjects that they are free to refuse entry into the study and  
free to withdraw from the study at any time without prejudice to future treatment.  Subjects will be consented for 
two years  or for the duration of the subject’s participation in the study .  
13.2 INSTITUTIONAL REVIEW BOARD (IRB)  
This study must be approved by an appropriate IRB at each registry  site. Securing the approval is the responsibility 
of the Investigator, as defined by ISO 14155 -1 and FDA regulations (21 CFR Part 56) prior to enrolling in the study.  
The Sponsor must recei ve a copy of the IRB approval letter (or equivalent documentation) for the study protocol 
and Informed Consent Form before the site can be activated to enroll patients . 
The IRB and Sponsor must approve any significant changes to the protocol , as well as a change of Principal 
Investigator. Documentation of IRB approval must be provided to the Sponsor. Records of all study review and 
approval documents must be maintained by the Investigator in the Study File/ Regulatory Binder and are subject to 
inspection by the Sponsor  (or designee)  or regulatory authority during or after completion of the study.  
The Investigator must notify the IRB, as per their reporting guidelines, and the Sponsor when he or she deviates from the protocol  (see Section 11.3  above) . The Spo nsor must be notified of all relevant action taken by the IRB 
and must receive a copy of all study -related correspondence between the Investigator and the IRB.  
The IRB must  receive notification of study  completion and  a final report upon  study completion or closure . A copy 
of these reports must be provided to the Sponsor. The Investigator must maintain an accurate and complete record of all submissions made to the IRB.  
13.3 CONFIDENTIALITY REGARDING STUDY SUBJECTS  
The Investigator must ensure that th e privacy of all subjects, including their personal identity and all personal 
medical information, will be maintained at all times. In CRFs and other documents or image material submitted to the Sponsor, subjects will not be identified by their names, but by an individual identification code (i.e., subject 
identification number).  
Personal medical information may be reviewed for the purpose of verifying data recorded in the CRFs. A  monitor 
or designee may conduct source -document verification on behalf of the  Sponsor, the quality assurance unit, or 
regulatory authorities. Personal medical information will always be treated as confidential and handled in 
compliance with the Health Insurance Portability and Accountability Act (HIPAA) . 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 32 of 39 
 13.4 INDEPENDENT  MEDICAL MONITOR  
An independent Medical Monitor, an independent physician who is  not a participant in the study , will review AEs 
that occur throughout the course of the study . The activities of the Medical Monitor will be guided by the Safety 
Plan . The Medical Monitor will be responsible for classifying events by severity, relationship, and seriousness , as 
well as  whether they meet MAE criteria related to the primary safety endp oint. For the Primary Analysis , the 
Medical Monitor AE assessments will supersede those of the Investigators when there are differences.  
13.5 CORE LABORATORY  AND IMAGE TRANSFER  
A central C ore Laboratory will independently evaluate venographic  imaging data collected at participating 
institutions. All protocol -required  venograms  must  be sent to the Core Laboratory for evaluation. Refer to the Core 
Laboratory  Imaging Manual for instructions for submitting data.  IVUS images will  also be sent  to the  Core 
Laboratory for possible future measurements . 
13.6 PARTICIPATING INSTITUTIONS AND INVESTIGATORS  
Study sites and Investigators will be selected based on a variety of factors including, but not limited to, experience 
with endovascular techniques, access to r equired facilities and equipment, sufficient and adequately trained 
personnel, and availability of potential subjects. The criteria used for determination will be documented.   
13.7 INVESTIGATOR RESPONSIBILITIES  
Investigator responsibilities include, but are not limited to, the following:  
• Conducting the study in accordance with this investigational plan, signed agreements , and applicable 
regulations protecting the rights and safety of study subjects  (e.g. IRB reporting requirements)  
• Ensuring that informed consent is obtained for each study subject in accordance with the investigational 
plan  
• Ensuring that IRB approval is sec ured prior to starting the study and ensuring continuing review and 
approval as required throughout the study  
• Ensuring all associates, colleagues, and employees assisting in the conduct of the study are informed about 
their obligations, are adequately qual ified and trained, and meet their commitments  
• Maintaining adequate and accurate records and ensuring those records are available for inspection at any 
time  
• Ensuring that conducting the study does not give rise to conflict of interest (financial disclosure is required)  
 
14 ELECTRONIC  DATA  
Electronic data capture (EDC) will be utilized for data collection in this study.  The study EDC will only be accessible 
to trained, authorized personnel with  a unique user identifier  and password  used to access the system . Passwords 
will be  set to expire periodically. Access to electronic study data will be provided to research personnel upon 
completion of training. Read and write access will be provided to registry  sites but only for information and subject 
data at their own site. The CRO and Sponsor  will have read -only access and can post queries for potential data -
related discrepancies.  Data will be reviewed, queried, cleaned and locked according to the study -specific Data 
Management Plan.   
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 33 of 39 
 15 DEFINITIONS  
The following definitions will be used throughout the course of the study:  
Term  Definition  
Primary Safety Endpoint Definitions  
Target venous segments  
(TVS)  The thrombus -containing  venous segments, specified by the operator, that were 
treated  with the study device at the index procedure.  
• These segments may include the popliteal vein, caudal femoral vein, cranial 
femoral vein, prof unda/deep femoral vein, common femoral vein, external iliac 
vein, internal iliac vein, common iliac vein, or the inferior vena cava.  
• This includes  segments that were treated  with the study device, irrespective of 
the pre -procedure plan.  
• This does not  include segments that were not intentionally treated but were 
instead passed through to remove the device from the leg  
Primary Analysis 
population The first 91 s ubjects with uni lateral acute or subacute DVT of less than or equal to 6 
weeks’ duration, without recent (≤3 month) history of venous interventions.  
Major adverse event  
(MAE)  A composite of events through 30 days that include a ll-cause mortality, major 
bleeding, new symptomatic PE documented by CTPA, or rethrombosis of a TVS  in 
the Primary Analysis  population.  
MAE: All -cause mortality  
(≤30 days)  Death from any cause, irrespective of relationship  to the device or to the procedure . 
MAE: Major bleeding  
(≤30 days)  Clinically overt  bleeding  that is associated by a fall in the hemoglobin of ≥ 5 g/dL, 
transfusion of ≥2 units of red blood cells, or involvement of a critical site (e.g. intracranial or int raspinal).  
• Hemoglobinuria is not considered to be clinically -overt and, as such, would in 
and of itself not constitute major bleeding.   
MAE: New s ymptomatic 
pulmonary embolism  (PE) 
(≤30 days)  New PE  accompanied by symptoms such as dyspnea, chest pain, or other localized 
symptoms referable to the event.   
• PE that is present at baseline but does not worsen  by evidence with additional 
emboli confirmed via CTPA does not trigger  the MAE definition.  
• New, symptomatic PE documented with CTPA but without a baseline imaging 
study will trigger  the MAE.  
MAE: Target vessel 
segment (TVS) 
rethrombosis  
(≤30 days)  Occlu sive thrombosis of a TVS that occurs after patency had previously been 
restored  in the segment, documented by imaging study such as duplex ultrasound, 
venography, computed tomographic venography, or magnetic resonance 
venography.  
• Rethrombosis requires ima ging documentation  of an open TVS  at the end of 
after the index procedure, with imaging documentation of occlusion of the segment thereafter.   
• Rethrombosis can be device -related (for example, from vascular injury caused 
by the study device), or non  device -related (for example, from inadequate 
anticoagulation).  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 34 of 39 
 Term  Definition  
Primary Effectiveness Endpoint Definitions  
Technical success  Complete or near complete removal of venous thrombus from the TVS, as 
determined by the percent reduction in the Marder score for those segments.  
• When more than one venous segment is treated, the change in Marder score is calculated as the total score for  the treated segments prior to intervention 
with the study device (baseline score) minus the total score after treatment with the study device but before treatment with any adjunctive devices or 
pharmacologic agents (post- treatment score), divided by the b aseline score.  
Additional Safety Definitions  
Adverse event  (AE) An AE is an untoward medical occurrence or exacerbation of an existing medical 
condition subsequent to  treatment with the ClotTriever .  
Serious adverse event  
(SAE)  An adverse event that me ets at least one of the following: is fatal; is life -
threatening; results in persistent or significant disability/incapacity; results in permanent impairment of a body function or permanent damage to a body 
structure; results in hospitalization or prolongs  a hospitalization; or necessitates 
medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure.  
Device -related event  An event that can be directly attributed  to the use of the device, where in, if the 
device functioned 100% to specifications and expectations, the event would not 
have occurred.  
• Rethrombosis in the absence of device induced vascular trauma  (documented 
on an imaging  study or with direct visualization of the vessel)  is not device -
related; rather it is a complication related to ineffective  anticoagulation 
therapy.   
• Perforation from the study device is device -related, but perforation from a 
non-study adjunctive  device is not.   
• As well, events that occur as a result of downstream venous compression (e.g., 
May -Thurner syndrome) are not considered device -related.  
Proced ure-related event  An event that is not device -related and occurs as a result of the procedure.  
• Events that occur ≤30 days  of the index procedure or ≤ 30 days of a secondary 
procedure performed for a previous procedure -related  complication, if the  
event is  not device -related.  
• Examples include complications from ineffective anticoagulation (e.g. 
rethrombosis ), excessive anticoagulation  (e.g. bleeding), or  vascular access 
with a non -study device (e.g.  generic sheath, guidewire injury) ; distant 
complications (e.g.  myocardial infarction, pneumonia ); or contrast- induced 
complicat ions (e.g. contrast -induced nephropathy or hypersensiti vity reaction).   
Reportable adverse event  Reportable AEs include all ev ents considered in the safety analyses, all device - 
and/or procedure -related AEs, as well as any event resulting in death.  
Minor bleeding  Bleeding that does not meet the MAE definition for Major Bleeding.  
• Mild oozing that occurs at an access puncture site and uncomplicated 
hemoglobinuria are not reported  as minor bleeding events.  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 35 of 39 
 Term  Definition  
Other Definitions  
Access site  The venous site used to gain access with the study device at the index procedure.  
Adjunctive Therapy  Per CLOUT protocol, adjunctive therapy is defined as an additional thrombus 
removal strategy after  ClotTriever thrombectomy has been completed  (i.e. balloon, 
stenting, and placement of IVC filters during ClotTriever procedure session would 
NOT be considered adjunctive therapy).  
Deep venous thrombosis  
(DVT ) Formation of thrombus within a deep vein, exclusive of non -thrombotic external 
compression or scarring of the wall.  
Acute (DVT)  Suspected timeframe of the onset of DVT is ≤14 days pre viously, as determined by 
the Investigator.  
Chronic DVT DVT that, in the Investigator’s opinion, began more than 6 weeks previously.  
Distal DVT  Distal DVT occur in the veins of the calf, most frequently in the posterior tibial and 
peroneal veins, and less frequently in the anterior tibial and soleal/gastrocnemius 
veins .  
Patency Primary patency means that you perform a procedure to restore patency to a 
vessel, and report how long patency is maintained without any repeat intervention.  
Primary -assisted patency defines the durability of an intervention that failed 
initially but not to the level of thrombosis and was retreated.  
Secondary patency means that the initial intervention failed to the level of 
thrombosis and was retreated. Once the second treatment was successfully 
performed, secondary patency defines the durability of that  second intervention.  
Proximal DVT  Proximal DVT is defined when the process involves the iliac, deep femoral, or 
popliteal veins.  
Subacute DVT DVT that, in the Investigator’s opinion, began >14 days but ≤6 weeks previously.  
Target limb  The limb referable to the TVS. In the case of bilateral  treatment , both limbs are 
target limbs.  
  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 36 of 39 
 16  REFERENCES  
1. Wadajkar AS, Santimano S, Rahimi M, Yuan B, Banerjee S, Nguyen KT. Deep vein thrombosis: current status 
and nanotechnology advances. Biotechnol Adv 2013;31:504- 13. 
2. Venous Thromboembolism (Deep Venous Thrombosis & Pulmonary Embolism). 2012. (Accessed February 17, 
2018, at https://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/venous -
thromboembolism/#bib8 .) 
3. Overview of the treatment of lower extremity deep vein thrombosis (DVT). 2018. (Accessed February 17, 2018, at 
http s://www -uptodate -com.proxy.uchicago.edu/contents/overview -of-the-treatment- of-lower -
extremity -deep -vein-thrombosis -
dvt?search=deep%20vein%20thrombosis&source=search_result&selectedTitle=1~150&usage_type=default&d
isplay_rank=1 .) 
4. Landefeld CS. Noninvasive  diagnosis of deep vein thrombosis. JAMA 2008;300:1696- 7. 
5. Comerota AJ. Practical Phlebolo gy: Deep Vein Thrombosis. Boca Raton FL: CRC Press; 2014.  
6. Byrnes JR, Wolberg AS. New findings on venous thrombogenesis. Hamostaseologie 2017;37:25- 35. 
7. Colucci ello SA. Deep Vein Thrombosis: Risk Factor Assessment and Diagnosis. In: Bosker G, ed. Textbook of 
Adult and Pediatric Emergency Medicine. Atlanta, GA: American Health Consultants; 2002.  
8. Freedman JE, Loscalzo J. Arterial and Venous Thrombosis. In: Long DL, ed. Harrison’s Principles of Internal 
Medicine. 18 ed. New York: McGraw -Hill Medical; 2012.  
9. Blann AD. Deep Vein Thrombosis and Pulmonary Embolism: A Guide for Practitioners. 2 ed. Cumbria UK: M&K Publishing; 2015.  
10. Furie B, Furie BC. Mechanisms o f thrombus formation. The New England journal of medicine 2008;359:938 -49. 
11. Schleimer K, Barbati ME, Gombert A, Wienert V, Grommes J, Jalaie H. The Treatment of Post -Thrombotic 
Syndrome. Dtsch Arztebl Int 2016;113:863- 70. 
12. Kucher N. Clinical practice . Deep -vein thrombosis of the upper extremities. N Engl J Med 2011;364:861- 9. 
13. Tovey C, Wyatt S. Diagnosis, investigation, and management of deep vein thrombosis. BMJ 2003;326:1180 -4. 
14. Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiolog ic Aspects. Circulation research 
2016;118:1340- 7. 
15. Thrombosis: a major contributor to global disease burden. Thrombosis research 2014;134:931 -8. 
16. Fernandez MM, Hogue S, Preblick R, Kwong WJ. Review of the cost of venous thromboembolism. ClinicoEconomics and outcomes research : CEOR 2015;7:451- 62. 
17. Mahan CE, Holdsworth MT, Welch SM, Borrego M, Spyropoulos AC. Deep -vein thrombosis: a United States 
cost model for a preventable and costly adverse event. Thrombosis and haem ostasis 2011;106:405- 15. 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 37 of 39 
 18. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. CHEST;149:315 -52. 
19. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, 
iliofemoral deep vein thrombosis , and chronic thromboembolic pulmonary hypertension: a scientific 
statement from the American Heart Association. Circulation 2011;123:1788- 830.  
20. Palareti G. How I treat isolated distal deep vein thrombosis (IDDVT). Blood 2014;123:1802- 9. 
21. Desai S, Mo watt -Larssen E, Azizzadeh A. Deep Vein Thrombosis. In: Mowatt- Larssen E, Desai S, Dua A, eds. 
Plebology, Vein Surgery and Ultrasonography. Switzerland: Springer International Publishing; 2014.  
22. Gary T, Belaj K, Steidl K, et al. Asymptomatic deep vein th rombosis and superficial vein thrombosis in 
ambulatory cancer patients: impact on short- term survival. British Journal of Cancer 2012;107:1244- 8. 
23. Chan NC, Eikelboom JW, Weitz JI. Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direc t 
Oral Anticoagulants. Circulation research 2016;118:1409- 24. 
24. Carter CJ. The natural history and epidemiology of venous thrombosis. Progress in cardiovascular diseases 1994;36:423- 38. 
25. Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical Catheter -Directed Thrombolysis for Deep -
Vein Thrombosis. The New England journal of medicine 2017;377:2240- 52. 
26. Finks SW, Trujillo TC, Dobesh PP. Management of Venous Thromboembolism: Recent Advances in Oral 
Anticoagulation Therapy. The Annals of pharma cotherapy 2016;50:486- 501.  
27. Warfarin and other VKAs: Dosing and adverse effectss. 2018. (Accessed February 20, 2018, at 
https://www -
uptodate -com.proxy.uchicago.edu/contents/warfarin -and-other -vkas -dosing -and-adverse -
effects?search=warfarin&source=search_result&selectedTitle=5~150&usage_ty pe=default&display_rank=5#H
38.) 
28. Prandoni P, Lensing AW, Prins MH, et al. Below -knee elastic compression stockings to prevent the post-
throm botic syndrome: a randomized, controlled trial. Annals of internal medicine 2004;141:249 -56. 
29. National Clinica l Guideline Center (UK). Venous Thromboembolic Diseases: The Management of Venous 
Thromboembolic Diseases and the Role of Thrombophilia Testing. London UK: Royal College of Physicians; 
2012.  
30. Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. The Cochrane database of systematic reviews 2016;11:Cd002783.  
31. Lattimer CR, Kalodiki E, Azzam M, Geroulakos G. Validation of the Villalta scale in assessing post -thrombotic 
syndrome using clinical, duplex, and hemodynamic comparators. J  Vasc Surg Venous Lymphat Disord 2014;2:8-
14. 
32. Vedantham S, Goldhaber SZ, Kahn SR, et al. Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter -directed thrombolysis for the prevention of 
postthrombotic syndrome in patients with proximal deep vein thrombosis. Am Heart J 2013;165:523 -30 e3.  
 
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 38 of 39 
 APPENDIX  1 KNOWN  RISKS  OF THROMBECTOMY   
 
Event Category Event  
Cardiac  Myocardial infarction  
 Congestive heart failure  
 Arrhythmia  
 Hypertension  
 Hypotension  
Wound  Wound infection 
 Wound pain 
 Wound dehiscence  
 Serous wound drainage  
 Lymphorrhea  
 Hematoma 
 Ecchymosis  
Peripheral vascular  Vessel perforation 
 False aneurysm formation  
 Arterial dissection  
 Mural thrombus formation  
 Vessel occlusion  
 Arteriovenous fistula  
 Distal embolization  
Venous  Deep venous thrombosis  
 Pulmonary embolism  
 Paradoxical embolization  
Cerebrovascular  Transient ischemic attack  
 Stroke  
 Intracranial hemorrhage  
Pulmonary  Exacerbation of chronic lung disease  
 Respiratory failure  
Miscellaneous  Sepsis  
 Death  
Inari Medical  
ClotTriever Thrombectomy System  Version 9.0 
August 12, 2020  
  
 
 
   
CLOUT Registry (Protocol 18 -001)       CONFIDENTIAL  Page 39 of 39 
 SIGNATURE  APPROVAL  PAGE  
CLotTriever OUT comes ( CLOUT ) Registry  
Protocol Number: 18 -001 
Version: 9.0 
August 12, 2020 
 
 This document contains confidential information for use only by Inari Medical . This document is not to be made 
available for review by unauthorized personnel. This document may not be reproduced without written permission.  
  
 
     Signed:  
Keith Hebert  
Senior Director, Clinical Research  
Inari Medical 
 
Aug 12, 2020
